Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris

“We are thrilled to reach this crucial milestone in our clinical program”, said Dr. Hermann Luebbert, CEO and Chairman of Biofrontera Inc. “The results of this Phase 2b study show promising reductions ...
clinicaladvisor.com

Actinic Keratoses: Field Cancerization and Photodynamic Therapy

Patients undergoing in-office treatment with PDT will have their skin cleansed with acetone and then undergo ALA application to the targeted treatment area. Incubation times will vary based on ...
Cure Today

Early Data Show Benefits With Ameluz-Photodynamic Therapy in Skin Cancer Subset

Ameluz-based photodynamic therapy achieved higher clearance rates in superficial basal cell carcinoma compared to placebo, with significant clinical and histological results. The study involved 187 ...
Seeking Alpha

Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

WOBURN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of ...
Nasdaq

Biofrontera Inc. Announces Last Patient Out in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Photodynamic Therapy (PDT) for the Treatment of Actinic ...

WOBURN, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of ...